Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02148536
NCT02148536
Completed
Not Applicable

Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome

West China Hospital1 site in 1 country64 target enrollmentJune 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHepatopulmonary Syndrome

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hepatopulmonary Syndrome
Sponsor
West China Hospital
Enrollment
64
Locations
1
Primary Endpoint
Alveolar-arterial oxygen gradient (PA-a,O2)
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

To prospectively investigate the effect of transjugular intrahepatic portosystemic shunt (TIPS) on oxygenation in cirrhotic patients with hepatopulmonary syndrome (HPS).

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
September 2015
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Xiao Li

Professor

West China Hospital

Eligibility Criteria

Inclusion Criteria

  • •Presence of cirrhosis
  • •Alveolar-arterial oxygen gradient ≥ 15 mm Hg (≥ 20 mm Hg for age \> 64 years)
  • •Positive contrast-enhanced echocardiography

Exclusion Criteria

  • •Age of less than 18 years
  • •Intrinsic cardiopulmonary disease
  • •Malignancy
  • •Active infection
  • •Pregnancy
  • •Previous shunt therapy
  • •Refusal to participate

Outcomes

Primary Outcomes

Alveolar-arterial oxygen gradient (PA-a,O2)

Time Frame: 12 Weeks

Secondary Outcomes

  • Macroaggregated albumin (MAA) shunt fraction(12 Weeks)
  • Exhaled nitric oxide (eNO)(12 Weeks)

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic PatientsCirrhosisAcquired Portal-systemic Shunt Due to CirrhosisHepatic Encephalopathy
NCT02427906West China Hospital50
Recruiting
Phase 2
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal HypertensionHepatocellular Carcinoma with PVTT
NCT06646198Fei Gao40
Completed
Not Applicable
The impact of trans-jugular intrahepatic portosystemic shunts on muscle mass in chronic liver disease.cirrhosisportal hypertensionsarcopeniaTrans-jugular intrahepatic portosystemic shuntOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonMusculoskeletal - Other muscular and skeletal disorders
ACTRN12619000081112Department of Gastroenterology and Hepatology, Austin Health14
Completed
Not Applicable
Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced CirrhosisDecompensated CirrhosisBleeding Varices
NCT01370161Air Force Military Medical University, China132
Withdrawn
Not Applicable
The effects of Transjugular Intrahepatic Portosystemic Shunt placement on von Willebrand factor levels in plasma of patients with cirrhosis and portal hypertension.
NL-OMON38711niversitair Medisch Centrum Groningen16